![Amy Vandekop](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Amy Vandekop
Plus aucun poste en cours
Fortune : 3 830 $ au 31/08/2026
Profil
Ms. Amy Vandekop, CPA, is a Chief Accounting Officer & Controller at Kalaris Therapeutics, Inc. Ms. Vandekop was previously employed as a Senior Director-Accounting & Reporting by AlloVir, Inc. and a Senior Manager-Accounting & Reporting by Lumicell, Inc. She received her undergraduate degree from the University of Massachusetts Amherst.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0 % | 27/08/2026 | 948 ( 0 % ) | 3 830 $ | 31/08/2026 |
Postes actifs de Amy Vandekop
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Amy Vandekop
| Sociétés | Poste | Fin |
|---|---|---|
| ALLOVIRPAR | Comptroller/Controller/Auditor | 01/03/2025 |
Lumicell, Inc.
 Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops and markets image-guided cancer surgery solutions | Comptroller/Controller/Auditor | 01/12/2020 |
Formation de Amy Vandekop
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
30
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Lumicell, Inc.
Lumicell, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops and markets image-guided cancer surgery solutions | Electronic Technology |
AlloVir, Inc.
 AlloVir, Inc. BiotechnologyHealth Technology Develops cellular immunotherapies for severe infections | Health Technology |
University of Massachusetts Amherst
 University of Massachusetts Amherst Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
